SCHEMBL13623526

SCHEMBL13623526

CS(=O)(=O)CS(=O)(=O)C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA13 Q8N1Q1 1/20 0.33
EPHX1 P07099 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL65750 0.81 CA1 (0.41) CA1CA2CA7CA13EPHX1
SCHEMBL13655656 0.78 EPHX1 (0.34) CA1CA2CA7CA13EPHX1
SCHEMBL8665505 0.78 CA1 (0.39) CA1CA2CA7CA13EPHX1
SCHEMBL7155965 0.78 CA1 (0.39) CA1CA2CA7CA13EPHX1
SCHEMBL9150994 0.78 CA1 (0.39) CA1CA2CA7CA13EPHX1
Hydrochloric Acid SCHEMBL9151279 0.73 CA1 (0.35) CA1CA2CA7CA13
SCHEMBL15145005 0.73 CA1 (0.35) CA1CA2CA7CA13
SCHEMBL13672704 0.73
Hydrochloric Acid SCHEMBL9151764 0.73 CA1 (0.35) CA1CA2CA7CA13
SCHEMBL21824 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160327858-A1 COLORING COMPOSITION, CURED FILM, COLOR FILTER, METHOD FOR MANUFACTURING COLOR FILTER, SOLID-STATE IMAGING DEVICE, AND IMAGE DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2016-11-10 US disclosed
US-20160256459-A1 SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE SIGNAL PHARM LLC (US) 2016-09-08 US disclosed
US-9365524-B2 Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use SIGNAL PHARMACEUTICALS, LLC (US) 2016-06-14 US disclosed
US-20160126594-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY FUJIFILM CORPORATION (JP) 2016-05-05 US disclosed
US-9231278-B2 Electrolyte solution for magnesium battery and magnesium battery containing this electrolyte solution NATIONAL UNIVERSITY CORPORATION NAGOYA INSTITUTE OF TECHNOLOGY (JP) 2016-01-05 US disclosed
US-9204652-B2 Antibacterial agent, substrate surface treatment method using the same, antibacterial agent composition, and substrate surface treatment method using the same CENTRAL GLASS COMPANY, LIMITED (JP) 2015-12-08 US disclosed
US-9204652-B2 Antibacterial agent, substrate surface treatment method using the same, antibacterial agent composition, and substrate surface treatment method using the same CENTRAL GLASS COMPANY, LIMITED (JP) 2015-12-08 US disclosed
US-20150311564-A1 ELECTROLYTIC SOLUTION FOR NON-AQUEOUS SECONDARY CELL, NON-AQUEOUS SECONDARY CELL, AND ADDITIVE FOR ELECTROLYTIC SOLUTION FUJIFILM CORPORATION (JP) 2015-10-29 US disclosed
US-20150210650-A1 SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE SIGNAL PHARMACEUTICALS LLC 2015-07-30 US disclosed
US-8986893-B2 Battery, battery pack, electronic apparatus, electrically driven vehicle, electrical storage device, and electric power system SONY CORPORATION (JP) 2015-03-24 US disclosed
US-20140242473-A1 ELECTROLYTE SOLUTION FOR MAGNESIUM BATTERY AND MAGNESIUM BATTERY CONTAINING THIS ELECTROLYTE SOLUTION TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) 2014-08-28 US disclosed
US-20130196190-A1 BATTERY, BATTERY PACK, ELECTRONIC APPARATUS, ELECTRICALLY DRIVEN VEHICLE, ELECTRICAL STORAGE DEVICE, AND ELECTRIC POWER SYSTEM SONY CORPORATION (JP) 2013-08-01 US disclosed
US-20130189220-A1 Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same CENTRAL GLASS COMPANY, LIMITED (JP) 2013-07-25 US disclosed
US-20130189220-A1 Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same CENTRAL GLASS COMPANY, LIMITED (JP) 2013-07-25 US disclosed
US-7618683-B2 Ink composition, inkjet recording method, printed material, process for producing lithographic printing plate, and lithographic printing plate FUJIFILM CORPORATION (JP) 2009-11-17 US disclosed
US-7419760-B2 Top anti-reflective coating composition, method for forming the pattern of a semiconductor device using the same, and semiconductor device comprising the pattern HYNIX SEMICONDUCTOR INC. (KR) 2008-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130189220-A1 Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same SEM1, CD81, VMA21 CA1 1812/4885CA2 2032/4885CA7 1090/4885
US-20150210650-A1 SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE TERT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPMT CA1 3033/4885CA2 4183/4885CA7 2905/4885
US-20160256459-A1 SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE TERT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPMT CA1 3033/4885CA2 4183/4885CA7 2905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.